GenomeWeb Reports on Epiontis Acquisition
GenomeWeb covers Precision for Medicine’s recent acquisition of Epiontis, summarizing Precision’s busy year of growth and highlighting the expanded capabilities now available to clients. (more…)
Precision for Medicine Acquires Epiontis—a Leading Immune Monitoring and Epigenetic Technology Service Provider
ADDITION OF BERLIN-BASED LAB EXPANDS PRECISION’S LARGE ARRAY OF IMMUNE MONITORING CAPABILITIES AND BOLSTERS GLOBAL FOOTPRINT
Bethesda, MD and Berlin, Germany – October 4th, 2017 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Berlin-based Epiontis GmbH, a next-generation European specialty laboratory providing immune monitoring services through a novel, patent-protected epigenetic platform. The acquisition adds Epiontis’s unique epigenetic technology and expertise to Precision’s robust suite of immune monitoring services for clinical trials, bringing additional value and capabilities to clients. It expands Precision’s growing global footprint and further positions the company as a scientific frontrunner in the rapidly expanding precision medicine space.
Precision Launches New All Access Newsletter for Market Access Leaders
Precision for Value is excited to be debuting a new publication– the Precision All Access Newsletter. All Access is an exclusive bi-monthly publication featuring key insights from our team of former payers intended specifically for market access leaders. (more…)
Dan Renick Talks Precision Value & Health With Healthcare Analytics News
Precision Value & Health President Dan Renick speaks with Ryan Black from Healthcare Analytics News, discussing the evolution of precision medicine and the importance of demonstrating value for new therapies to encourage reimbursement. (more…)
Galante Emphasizes the Patient Perspective for Clinical Leader
Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny—all while trying to satisfy investors. (more…)